Allergan ophthalmic news

India's Intellectual Property Appellate Board (IPAB) invalidated two patents held by Allergan for ophthalmic drugs Ganfort bimatoprost/timolol and Combigan brimonidine/timolol, citing obviousness in both cases. Ganfort is a fixed-dose of 0.03% bimatoprost, a prostaglandin analog, and 0.5% timolol, a beta adrenenergic receptor inhibitor. Combigan is a combination of 0.2% brimonidine, an alpha adrenergic receptor agonist, and timolol. Allergan markets Ganfort and Combigan to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. ...